Literature DB >> 1434533

Prostate cancer: therapeutic, diagnostic, and basic studies.

M E Stearns1, T McGarvey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1434533

Source DB:  PubMed          Journal:  Lab Invest        ISSN： 0023-6837            Impact factor:   5.662


× No keyword cloud information.
  6 in total

1.  Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer.

Authors:  Z Kolár; P G Murray; K Scott; A Harrison; B Vojtĕsek; J Dusek
Journal:  Mol Pathol       Date:  2000-02

2.  Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

Authors:  A P Stubbs; P D Abel; M Golding; G Bhangal; Q Wang; J Waxman; G W Stamp; E N Lalani
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

3.  The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.

Authors:  Michael J Willhauck; Bibi-Rana Sharif Samani; Ingo Wolf; Reingard Senekowitsch-Schmidtke; Hans-Jürgen Stark; Geerd J Meyer; Wolfram H Knapp; Burkhard Göke; John C Morris; Christine Spitzweg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-11       Impact factor: 9.236

4.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

Authors:  J A Ruizeveld de Winter; P J Janssen; H M Sleddens; M C Verleun-Mooijman; J Trapman; A O Brinkmann; A B Santerse; F H Schröder; T H van der Kwast
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

5.  Genetic alterations in hormone-refractory recurrent prostate carcinomas.

Authors:  N N Nupponen; L Kakkola; P Koivisto; T Visakorpi
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

6.  Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Authors:  P Koivisto; E Hyytinen; C Palmberg; T Tammela; T Visakorpi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.